Retour à la liste des essais cliniquesCancers gynécologiques

DS6000-109

A Phase 2/3, Multicenter, Randomized Study of Raludotatug;Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate,;in Subjects with Platinum-resistant, High-grade Ovarian, Primary;Peritoneal, or Fallopian Tube Cancer.

Ouvert à Saint-Cloud depuis le : 11/10/2024
Public cible : Adult
Phase : Phase II/III

Description de l'essai

To evaluatecBICR-assessed ORRcat each dose level of;R-DXd.;To evaluate investigator-assessed ORR at each dose;level of R-DXd.;To evaluate the DoR at each dose level of;R-DXd.

Url of the trial

Investigateur principal

DIANA BELLO ROUFAI

Médecin

Contacter